L
Lanthio Pharma
Developing and commercializing lanthipeptides as innovative drugs for treating medical conditions
About Lanthio Pharma
Lanthio Pharma is a Dutch biopharmaceutical company focused on discovering and developing therapeutic peptides for severe diseases with high unmet medical need. The company operates in the biopharmaceutical market, primarily targeting oncology and critical care medicine. Utilizing proprietary lanthionine-constrained peptide technology, Lanthio Pharma creates peptides with superior target selectivity and stability. These peptides are designed to interact specifically with certain receptors, making them highly effective for therapeutic use. The company's business model revolves around research and development, clinical trials, and eventual commercialization of these therapeutic peptides. Revenue is generated through partnerships, licensing agreements, and government grants. Lanthio Pharma serves clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Groningen, Netherlands
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
BioGeneration Ventures
Inkef
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lanthio Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lanthio Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.